Menu
← Oncology Approval Tracker
FDA DECISION ·
Hyrnuo
sevabertinib · Bayer Healthcare Pharmaceuticals
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
For adults with locally advanced or metastatic nonsquamous NSCLC with a HER2 (ERBB2) activating tyrosine kinase domain mutation by an FDA-approved test after prior systemic therapy.
LAMPGEN ANALYSIS
Why it matters
Accelerated approval added another oral kinase inhibitor option for previously treated HER2-mutated nonsquamous lung cancer.
What research teams should watch
Record prior HER2-directed therapy, retain the exact qualifying variant, and coordinate follow-up for confirmatory evidence.
PRIMARY RECORDS